🇺🇸 Methylxanthine in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 11

Most-reported reactions

1. Dyspnoea — 2 reports (18.18%)
2. Activities Of Daily Living Impaired — 1 report (9.09%)
3. Cardiac Arrest — 1 report (9.09%)
4. Chronic Obstructive Pulmonary Disease — 1 report (9.09%)
5. Cough — 1 report (9.09%)
6. Dysphonia — 1 report (9.09%)
7. Emphysema — 1 report (9.09%)
8. Immunodeficiency — 1 report (9.09%)
9. Lung Disorder — 1 report (9.09%)
10. Pneumonia — 1 report (9.09%)

Source database →

Frequently asked questions

Is Methylxanthine approved in United States?

Methylxanthine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Methylxanthine in United States?

National Heart, Lung, and Blood Institute (NHLBI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.